Hansoh and GSK’s HS-20093 Receives FDA Breakthrough Therapy Designation for Osteosarcoma
China-based Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692) and its UK partner GSK plc (LON:...
Boehringer Ingelheim China and Shanghai Pharmaceuticals Holding Co. Launch Strategic Partnership for Linagliptin
On January 7, Boehringer Ingelheim China and Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607,...
Merck KGaA Completes Acquisition of HUB Organoids, Expanding Cell Culture Portfolio
German major Merck KGaA (ETR: MRK) announced the completion of its acquisition of Holland-based HUB...
Amgen’s Imdylltra Gains Conditional Approval in UK for Extensive-Stage Small Cell Lung Cancer
US biotech company Amgen (NASDAQ: AMGN) has received conditional approval from the UK’s Medicines and...
Mabwell Bioscience Files for IPO on Hong Kong Stock Exchange, Expanding Biopharma Reach
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has officially filed for an initial public offering...
WuXi Biologics to Sell Irish Vaccine Assets to MSD for USD 500 Million
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) is poised to...
Junshi Biosciences’ Loqtorzi Gains Regular Approval for Melanoma Treatment in China
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that its PD-1 inhibitor,...
Simcere Zaiming’s SIM0505 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors
China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary, Simcere Zaiming, has announced that it has...
NMPA Releases 88th Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 88th batch of reference drugs for...
Huahui Health’s HH-003 Gains Priority Review Status for Chronic Hepatitis D Treatment
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has indicated...
WuXi Biologics and Candid Therapeutics Ink Global Research Agreement for Trispecific T-cell Engager
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...
Amoytop Biotech’s Pegfilgrastim Gains NMPA Approval for Preeclampsia Clinical Trials
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced that it has received clinical trial...
Hengrui Pharmaceuticals Files IPO Prospectus in Hong Kong Amid Record Deal-Making
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has officially submitted an initial public offering (IPO)...
Changchun BCHT Partners with Baosight Software for Biopharmaceutical Digitization
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced a partnership with compatriot firm...
CDE Announces 90th Batch of Reference Preparations for GQCE
China’s Center for Drug Evaluation (CDE) has selected the 90th batch of reference preparations for...
Solasia Pharma Licenses Episil to GeneScience for Greater China Region
Japan-based Solasia Pharma K. K (TYO: 4597) has announced a licensing agreement with Changchun GeneScience...
Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines
Shanghai-based Alebund Pharmaceuticals has announced the completion of a Series C financing round, raising RMB...
GSK’s Nucala Receives New Indication Approval in China for CRSwNP
UK-based pharmaceutical company GlaxoSmithKline’s (GSK; NYSE: GSK) has announced that it has received another indication...
China’s Healthcare Bureaus Remove Drug Quantity Limits to Enhance NRDL Access
The healthcare security administration bureaus in Shanghai, Beijing, and other regions have recently removed limits...
Kexing Pharmaceutical Partners with Shandong Boan for Biosimilar Commercialization in Hong Kong and Macau
China-based Kexing Pharmaceutical (SHA: 688136) has entered into a commercialization cooperation agreement with fellow Chinese...